Alterity Therapeutics (PRNAD) Cash from Financing Activities (2016 - 2019)

Alterity Therapeutics (PRNAD) has reported Cash from Financing Activities for 4 consecutive years, with $166760.3 the latest figure, recorded in Q4 2019.

• In Q4 2019, Cash from Financing Activities rose 62.62% year-over-year to $166760.3; the TTM figure through Dec 2019 stood at $124416.7 (down 97.8% YoY), while the FY2025 annual figure was $25.4 million, up 318.28% from the prior year.
• Cash from Financing Activities came in at $166760.3 for Q4 2019 at Alterity Therapeutics, up from $102549.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $166760.3 in Q4 2019, with the low at -$115796.0 in Q4 2016.
• Average Cash from Financing Activities over 4 years is $31104.2, with a median of $36726.2 recorded in 2017.
• Across the five-year window, Cash from Financing Activities jumped 452.44% in 2018 and surged 62.62% in 2019, its largest moves.
• Year by year, Cash from Financing Activities stood at -$115796.0 in 2016, then surged by 74.87% to -$29096.6 in 2017, then surged by 452.44% to $102549.0 in 2018, then surged by 62.62% to $166760.3 in 2019.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $166760.3, $102549.0, and -$29096.6 for Q4 2019, Q4 2018, and Q4 2017 respectively.